Pemazyre 4.5 mg tablets clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
PEARLDIFER - A Phase II study of pemigatinib after curative local therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements
This study looks at a new tablet treatment called Pemazyre for a specific liver cancer in people who have already had surgery or other treatments. It aims to see if the medicine can stop the cancer from coming back and how people feel while taking it.
For: locally advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangementsGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
INCB 54828-801: An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib
This study is for people with advanced cancer who are already taking a medicine called pemigatinib and are getting good results from it. It allows them to keep receiving this medicine if they can't get it elsewhere, helping doctors understand more about its long-term effects and safety.
Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
This study is testing a new drug, pemigatinib, against standard chemotherapy for a type of bile duct cancer (cholangiocarcinoma) that has spread or can't be removed, and has a specific gene change. It wants to see which treatment works better and is safer as a first treatment.
For: CholangiocarcinomaGermany · Belgium · Italy